BBC Health Watcher

主にBBCニュースの記事で気になる医療・健康の話題についてのコメント

株の価値とは

2008-03-31 15:28:47 | 日記・情報メモ
株の価値とは、  (pp46-47, 新しい株の本)

毎年1万円の利益が、将来ずっと得られると想定して、
その期待利回りが 7%とすると、

妥当な株価 x 期待利回り(7%) = 毎年の利益 (1万円) (基本式)

妥当な株価 =毎年の利益 / 期待利回り
      =10,000/0.07 = 14,2857

従って、約14万円となる。

結局のとこと、期待利回りによる妥当の株価より、実際の価格が下回る場合は、「買い」、下回れば「売り」ということになる。


セルフイメージ

2008-03-28 16:24:15 | 日記・情報メモ
脳で意識をすると、それを達成するよう下意識が働き、意識した方向に体を動かそうとする。下意識は行動に必要な知識、経験、技能をフル活動させ、意識した行動を取るように働く巨大な技術工場である。更にセルフイメージは自分の思った結果、望む結果を出すように、その行動を制御するのである。


従って、セルフイメージは非常に重要である。

(1) セルフイメージ

(2) 目標の設定、- 考え、行動 -

(3) 結果、経験

5年、3年、1年毎のセルフイメージの改善が必要。


詳しくは、

http://www.ztv.ne.jp/web/tsu-hirota/mental/mental01.htm

BI Market

2008-03-26 08:54:55 | 日記・情報メモ
老舗BIベンダーは、大手に吸収され、残る独立系は、今後、オープンソリューションとTOCにて、生き残りを賭ける。

日本市場は、ブランド市場主義のため、いくら製品が良くても厳しい状況に、
変わりはないと思われる。


The death of the independent software firm is greatly exaggerated.

MicroStrategy (MSTR), SAS, Informatica (INFA), Actuate (ACTU) and Teradata (TDC) are just some of the independent firms that are probably getting tired of hearing that they are no longer viable.

After all, the titans did not take the market over, but rather they acquired companies – Business Objects (SAP), Cognos (IBM) and Hyperion (ORCL) - who were the market leaders. If, as the pundits proclaim, IT departments are only buying from the titans because they want “one throat to choke”

And, do the pundits examine IDC market share numbers? The titans and their acquired companies only had 37% of the market in 2006. That means nearly two-thirds (!) of the market is not buying the titans-only purchase plan. And most market share studies under-represent open source, on-demand software and emerging technologies provided by innovative independent software companies.

Innovative companies and emerging technologies generally come from independents and new ventures rather than the titans. On-demand software, open source software, data visualization, industry specific performance management solutions are just a few areas where the innovation is coming from the independents. And it seems companies are willing to buy that software from them.

Another reason why independents will continue to thrive is, besides innovation, they often provide a much lower TCO (total cost of ownership) that the titans. First, as the titans acquire and absorb companies and products the resulting product lines are almost always more complex and costly to use. The titans will point to increased functionality, but there is no free lunch to gaining that functionality; the customer pays for it in many ways.

Second, as a former software engineer, I am inclined to believe that as your product line continues to be expanded through acquisitions and products “integrated,” these product lines have increasing amounts of “kludges” to get the those products to work together. I know you can use SOA and services to “integrate” products, but these can be used as a modern band-aid to integration. Finally, the titans’ licensing schemes always seem to expand with each release and acquisition. The independents can much more easily under-price the titans.

Mergers and acquisitions (M&A) have always been part of the software industry. As any industry matures, M&A activity increases and consolidation is inevitable. You can make a persuasive case that software independents are unlikely to grow to be multi-billion titans themselves before they are acquired. But it is tough to make the case that many independents cannot exist and grow in this marketplace. The evidence does not support that case.

In addition, at various times in the last couple of decades pundits made the case that IBM, then Microsoft and then Oracle so dominated the landscape that independents could never grow and thrive. But somehow companies such as Business Objects, Cognos, Hyperion, PeopleSoft Seibel and many others grew to be large and then got acquired. And there are still many successful tech firms such as Google, SAS and SAP. And we have dozens of successful independents providing solutions that are being bought by companies across all industries.

Just look at the large pharmaceutical and medical device companies. They are behemoths that continue to grow organically and by acquisition. No one in that industry is declaring the biotechs dead just because they often get acquired. In fact, the biotechs are often the innovative companies.

http://seekingalpha.com/article/63757-death-of-the-independent-software-firm?source=yahoo



note:
exaggerate
If something exaggerates a situation, quality, or feature, it makes the situation, quality, or feature appear greater, more obvious, or more important than it really is.


参入市場について

2008-03-25 09:44:15 | 日記・情報メモ
参入市場の選び方:

のんびり・気迫がない、技術一本やり・職人気質・趣味的のキーワードに該当する市場は、あまり成熟していないが、ほんのちょっと勉強した会社が参入すると業界地図を塗り替えることが可能。

手法の優先順位:

(1)明朗会計
(2)統一イメージ
(3)顧客重視
(4)マーケティング(ホームページ・広告宣伝)